Sagar Nandi
Biotech Stock at possible Buy-Point.
 
In the Biotech Industry, regarding Fundamentals, I found EXEL to have one of the most attractive combinations of Valuation, Last Quarter EPS Growth, Last Quarter to Last Year Revenue Growth, Earnings Quality, and Short Squeeze potential.
 
Technically, the Stock made a False Downside Breakout and went up. The False Breakout was accompanied by Very High Volume. Probably it stopped out weak hands. Technical Daily charts showing low-risk (narrow Stop) buy point.
 
 
Chart: EXEL Daily (17th May 11:30 AM EST)

EXEL.jpg 
1

Disclaimer: This site is for educational purposes only, explaining the use of CUE systems and techniques. It is not for trade advice. Trading involves risk. You and only you are solely responsible for the outcome of your trades.

CUE Elite
CUE Global & CUE Finder
CUE Edge, Vital, Index
Metastock Software (One-Time)
Metastock Data/Subscription
Data Region